Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 7/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 3/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL697088 | 1.00 | BTK (0.51) | BTKDRD2KDM1AMAOBEPHX1 | |
| SCHEMBL1543495 | 1.00 | BTK (0.51) | BTKDRD2KDM1AMAOBEPHX1 | |
| SCHEMBL6643451 | 0.91 | BTK (0.56) | BTKDRD2KDM1AMAOBEPHX1 | |
| SCHEMBL16856527 | 0.91 | BTK (0.56) | BTKDRD2KDM1AMAOBEPHX1 | |
| SCHEMBL3900948 | 0.91 | BTK (0.56) | BTKDRD2KDM1AMAOBEPHX1 | |
| SCHEMBL28480020 | 0.87 | DRD2 (0.48) | BTKDRD2KDM1AMAOBEPHX1 | |
| SCHEMBL30942791 | 0.87 | DRD2 (0.48) | BTKDRD2KDM1AMAOBEPHX1 | |
| SCHEMBL1067922 | 0.86 | BTK (0.50) | BTKDRD2KDM1AMAOBEPHX1 | |
| SCHEMBL13202379 | 0.86 | DRD2 (0.47) | BTKDRD2KDM1AMAOBEPHX1 | |
| SCHEMBL946942 | 0.86 | BTK (0.50) | BTKDRD2KDM1AMAOBEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113527227-B | Preparation method of kalirazine | 四川弘远药业有限公司 | 2024-06-21 | — | — | CN | claimed |
| CN-117800875-A | Preparation method of trans- (N-Boc-4-aminocyclohexyl) acetic acid | 泰州精英化成医药科技有限公司 | 2024-04-02 | — | — | CN | claimed |
| CN-114539184-A | Preparation method of cariprazine intermediate | 泰州精英化成医药科技有限公司 | 2022-05-27 | — | — | CN | claimed |
| CN-114213362-A | Preparation method of cariprazine and intermediate compound | 成都栩哲医药科技有限公司 | 2022-03-22 | — | — | CN | claimed |
| CN-113527227-A | Preparation method of cariprazine | 成都弘达药业有限公司 | 2021-10-22 | — | — | CN | claimed |
| CN-113493399-A | Preparation method for converting configuration of key intermediate of cariprazine | 北京万全德众医药生物技术有限公司 | 2021-10-12 | — | — | CN | claimed |
| US-12630512-B2 | Agents for differentiating stem cells and treating cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2026-05-19 | — | — | US | disclosed |
| US-12583839-B2 | PD-L1 antagonist compound | ADLAI NORTYE BIOPHARMA CO., LTD. (CN) | 2026-03-24 | — | — | US | disclosed |
| EP-3600451-B1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORP (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-2025230799-A2 | CYCLOALKYL- AND PIPERIDINYL-CONTAINING DIAMINOMETHYLENE PYRIMIDINE-2,4,6-TRIONE AGONISTS OF PARATHYROID HORMONE 1 AND INCRETIN RECEPTORS | SEPTERNA, INC. (US) | 2025-11-06 | — | — | WO | disclosed |
| EP-4608810-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS | Septerna, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250236632-A1 | BETA-LACTAMASE INHIBITORS | VENATORX PHARMACEUTICALS INC (US) | 2025-07-24 | — | — | US | disclosed |
| WO-2025151602-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-07-17 | — | — | WO | disclosed |
| US-20030018059-A1 | Serine protease inhibitors | PROTHERICS MOLECULAR DESIGN LIMITED (GB) | 2003-01-23 | — | — | US | disclosed |
| EP-1119562-A1 | 2,3-DIHYDRO-1H-ISOINDOLE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM PLC (GB) | 2001-08-01 | — | — | EP | disclosed |
| EP-1086095-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2001-03-28 | — | — | EP | disclosed |
| WO-2000021950-A1 | 2,3-DIHYDRO-1H-ISOINDOLE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-04-20 | — | — | WO | disclosed |
| WO-1999064412-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-12-16 | — | — | WO | disclosed |
| US-5977110-A | Substituted cyclohexylamines as central nervous systems agents | WARNER-LAMBERT COMPANY (US) | 1999-11-02 | — | — | US | disclosed |
| WO-1997011070-A1 | SUBSTITUTED CYCLOHEXYLAMINES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER-LAMBERT COMPANY (US) | 1997-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236632-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | BTK 524/4885DRD2 3783/4885KDM1A 447/4885 |
| US-20030018059-A1 | Serine protease inhibitors | TPSAB1, PRSS1, SERPINB1 | BTK 2793/4885DRD2 3971/4885KDM1A 876/4885 |
| US-12630512-B2 | Agents for differentiating stem cells and treating cancer | MCL1, POU2F1, NES | BTK 4615/4885DRD2 1863/4885KDM1A 723/4885 |
| US-12583839-B2 | PD-L1 antagonist compound | CD274, PDCD1LG2, PDCD1 | BTK 2199/4885DRD2 201/4885KDM1A 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.